Vyne Therapeutics Inc (VYNE) Stock Analysis — PE Ratio, PS Ratio, Intrinsic Value & 2030 Price Target
Vyne Therapeutics Inc stock (VYNE) is currently trading at $0.60. Vyne Therapeutics Inc PS ratio (Price-to-Sales) is 35.35. Analyst consensus price target for VYNE is $2.00. WallStSmart rates VYNE as Sell.
- VYNE PE ratio analysis and historical PE chart
- VYNE PS ratio (Price-to-Sales) history and trend
- VYNE intrinsic value — DCF, Graham Number, EPV models
- VYNE stock price prediction 2025 2026 2027 2028 2029 2030
- VYNE fair value vs current price
- VYNE insider transactions and insider buying
- Is VYNE undervalued or overvalued?
- Vyne Therapeutics Inc financial analysis — revenue, earnings, cash flow
- VYNE Piotroski F-Score and Altman Z-Score
- VYNE analyst price target and Smart Rating
Vyne Therapeutics Inc
📊 No data available
Try selecting a different time range
Smart Analysis
Vyne Therapeutics Inc (VYNE) · 7 metrics scored
Smart Score
Category Performance
WallStSmart pulls financial metrics like revenue growth, profit margins, and valuation ratios and scores each one from 0 to 10 based on how strong or weak it is. Those 10 scores are grouped into 4 categories: Growth, Profitability, Valuation, and Quality — which form the 4 axes of the spider chart you see. The categories are then combined into a final score out of 100, but not equally. Growth and Profitability together count for 60% of the total, because a fast-growing profitable business matters more than just a cheap one. That final number maps to a rating (Strong Buy, Buy, Hold, Avoid) and a letter grade, giving you one clear Stock Rating.
Investment Thesis
Strong fundamentals in price/book, revenue growth. Concerns around market cap and return on equity. Significant fundamental concerns warrant caution or avoidance.
Vyne Therapeutics Inc (VYNE) Key Strengths (2)
Trading below book value, meaning the market prices it less than net assets
Revenue surging 54.80% year-over-year
Supporting Valuation Data
Vyne Therapeutics Inc (VYNE) Areas to Watch (5)
Company is destroying shareholder value
Losing money on operations
Very expensive at 35.4x annual revenue
Micro-cap company with very limited liquidity and high volatility
Low institutional interest, mostly retail-driven
Supporting Valuation Data
Vyne Therapeutics Inc (VYNE) Detailed Analysis Report
Overall Assessment
This company scores 30/100 in our Smart Analysis, earning a F grade. Out of 7 metrics analyzed, 2 register as strengths (avg 10.0/10) while 5 fall into concern territory (avg 1.8/10). The category breakdown reveals uneven performance, with some areas requiring attention.
The Bull Case
The strongest argument centers on Price/Book, Revenue Growth. Valuation metrics including Price/Book (0.73) suggest the stock is attractively priced. Growth metrics are encouraging with Revenue Growth at 54.80%.
The Bear Case
The primary concerns are Return on Equity, Operating Margin, Price/Sales. Some valuation metrics including Price/Sales (35.35) suggest expensive pricing. Profitability pressure is visible in Return on Equity at -67.00%, Operating Margin at -4015.00%.
Key Dynamics to Monitor
Three factors to monitor going forward. First, whether Return on Equity improves, as this is the primary drag on the overall score. Second, margin trajectory, with Return on Equity at -67.00% needing improvement to support the investment thesis. Third, growth sustainability, with Revenue Growth at 54.80% strong but requiring continuation.
Risk Considerations
Based on the metric profile, this is a higher risk investment. There are more areas of concern than strength, warranting a more conservative position size. Investors should size positions according to their risk tolerance and maintain diversification.
Bottom Line
Fundamental challenges outweigh strengths at current levels. Return on Equity and Operating Margin are the primary drags. Consider waiting for meaningful improvement before committing capital.
Disclaimer: Smart Analysis is a scoring system developed by WallStSmart Team. Scores update daily using multi-model valuation framework. Always conduct your own research and consult with financial advisors before making investment decisions.
VYNE Price-to-Sales(PS) Ratio Chart
Historical valuation based on market cap ÷ trailing 12-month revenue
VYNE's Price-to-Sales ratio of 35.35x trades at a deep discount to its historical average of 81.74x (50th percentile). The current valuation is 92% below its historical high of 460.57x set in May 2023, and 2069% above its historical low of 1.63x in Nov 2021. Over the past 12 months, the PS ratio has compressed from ~112.9x as trailing revenue scaled faster than the stock price.
WallStSmart Analysis Synopsis
Data-driven financial summary for Vyne Therapeutics Inc (VYNE) · HEALTHCARE › BIOTECHNOLOGY
The Big Picture
Vyne Therapeutics Inc is in a high-growth phase, prioritizing rapid expansion over margins. Revenue reached 570,000 with 55% growth year-over-year.
Key Findings
Revenue growing at 55% YoY, reaching 570,000. This pace significantly outperforms most BIOTECHNOLOGY peers.
Spending 522% of revenue (3M) on R&D, reinforcing its commitment to innovation and future growth.
Free cash flow is -4M, meaning the company is burning cash. This may be acceptable for high-growth companies investing heavily.
What to Watch Next
Growth sustainability: can Vyne Therapeutics Inc maintain 55%+ revenue growth, or will competition slow it down?
Volatility is elevated with a beta of 2.03, so expect amplified moves relative to the broader market.
Sector dynamics: monitor BIOTECHNOLOGY industry trends, competitive moves, and regulatory changes that could impact Vyne Therapeutics Inc.
Bottom Line
Vyne Therapeutics Inc is a high-conviction growth story with revenue accelerating at 55% while profitability is still developing. For growth-oriented investors, the trajectory is compelling. For value investors, the thin 0.0% margins and premium valuation suggest patience until the unit economics mature further.
This synopsis is generated from publicly available financial data. It is not financial advice. Always conduct your own research and consult a qualified financial advisor before making investment decisions.
Insider Transactions
Loading insider activity...
About Vyne Therapeutics Inc(VYNE)
NASDAQ
HEALTHCARE
BIOTECHNOLOGY
USA
VYNE Therapeutics Inc., a pharmaceutical company, focuses on developing and commercializing various therapies for dermatology. The company is headquartered in Bridgewater, New Jersey.